首页 › 基金 › ACUTA CAPITAL PARTNERS, LLC › AVBP
ACUTA CAPITAL PARTNERS, LLC 对 AVBP 的持仓历史
ARRIVENT BIOPHARMA INC · 医疗保健
ACUTA CAPITAL PARTNERS, LLC 在 Q3 2026 的 13F 申报中披露持有 AVBP(ARRIVENT BIOPHARMA INC)170,893 股,市值约 US$5.2M,约占其申报组合的 4.08%,在其申报持仓中市值排名第 6 位。 ACUTA CAPITAL PARTNERS, LLC 最近 2 个申报季度中有 2 个季度披露了 AVBP 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
ACUTA CAPITAL PARTNERS, LLC 对 AVBP 的持仓演变
ACUTA CAPITAL PARTNERS, LLC 于 Q2 2026 首次披露 AVBP 持仓:218,694 股(约 US$7.6M)。 在 2 次申报中,ACUTA CAPITAL PARTNERS, LLC 0 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 170,893 股、市值约 US$5.2M,环比减持 -47,801 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 218.69K | $7.60M | 新进 |
| Q3 2026 | 170.89K | $5.17M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AVBP 与 13F 数据
AVBP(ARRIVENT BIOPHARMA INC)属于医疗保健行业。我们追踪的基金中还有 54 只申报持有 AVBP,申报仓位最大的包括:MONTANOVA CAPITAL, LLC (US$156.9M), INFINITUM ASSET MANAGEMENT, LLC (US$154.2M), 高瓴资本 (US$136.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AVBP 的基金
- MONTANOVA CAPITAL, LLC 4.52M 股 · $156.87M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.44M 股 · $154.19M · Q2 2026
- 高瓴资本 3.93M 股 · $136.50M · Q2 2026
- ORBIMED ADVISORS LLC 3.03M 股 · $105.17M · Q2 2026
- Octagon Capital Advisors LP 1.97M 股 · $68.47M · Q2 2026
- Vivo Capital, LLC 1.79M 股 · $54.11M · Q3 2026
- Novo Holdings A/S 1.50M 股 · $52.11M · Q2 2026
- General Catalyst Group Management, LLC 1.49M 股 · $51.93M · Q2 2026
- Sofinnova Investments, Inc. 1.70M 股 · $51.38M · Q3 2026
- Logos Global Management LP 1.35M 股 · $40.88M · Q3 2026
- HSG Holding Ltd 663.31K 股 · $20.08M · Q3 2026
- Foresite Capital Management VI LLC 301.34K 股 · $10.47M · Q2 2026
更多关于 ACUTA CAPITAL PARTNERS, LLC
常见问题
How long has ACUTA CAPITAL PARTNERS, LLC held AVBP?
ACUTA CAPITAL PARTNERS, LLC has disclosed AVBP holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is ACUTA CAPITAL PARTNERS, LLC's current position in AVBP?
As of Q3 2026, ACUTA CAPITAL PARTNERS, LLC holds 170.89K shares of AVBP (ARRIVENT BIOPHARMA INC), valued at $5.17M, representing 4.08% of its reported portfolio and ranking #6.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling AVBP?
In the latest 13F filing (Q3 2026), ACUTA CAPITAL PARTNERS, LLC reduced its position in AVBP.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, 高瓴资本, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.